Genomtec S.A.: Informacja produktowa: udzielenie ochrony patentowej na wynalazek (2024-02-28)

The Executive Board of Genomtec S.A. („Company”, „Issuer”) registered in Wroclaw, Poland, hereby reports that today The Company has learned about a positive decision of the Patent Office of the Republic of Poland granting the Company patent protection for an invention entitled „Zestaw starterów do powielania sekwencji nukleotydowej genu dnaE Mycoplasma pneumoniae, sposób wykrywania bakterii Mycoplasma pneumoniae, sposób wykrywania infekcji bakterią Mycoplasma pneumoniae oraz zestaw do wykrywania infekcji bakterią Mycoplasma pneumoniae”. Granting a patent is conditional on the Issuer paying the required official fees for which the Management Board of Genomtec S.A. has agreed.

The invention covers significant technical solutions related to the area of molecular biology of the Genomtec ID platform significantly affecting the diagnostic parameters of the RP5-Plex panel detecting the most common causes of respiratory infections.

The Issuer informs that this is the twelfth patent received by the Company. The Issuer is pending over thirty patent applications all over the world.

The Issuer's Management Board decided that the receipt of the above patent is confidential information, as in the case of an entity operating on the molecular diagnostics market, it is necessary to effectively protect intellectual and industrial property. Properly secured intellectual and industrial property may constitute the Issuer's competitive advantage - and its safe commercialization is possible provided that full protection is ensured on selected markets.

In the opinion of the Management Board, a high level of intellectual property protection will also provide the Company with an appropriate negotiating position before signing commercial agreements with selected partners in the scope of implementing the commercialization strategy.

Patent proceedings are aimed at securing key interests and are in line with the Issuer's development strategy, which includes building a portfolio of intellectual property rights. POCT diagnostics using the Genomtec ID platform is the key area of the Issuer's operations. For these reasons, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Art. 7 sec. 1 MAR.